Outcome of allotransplants in patients with chronic-phase chronic myeloid leukemia following imatinib failure: Prognosis revisited

Anticancer Research

Volumn 33, Issue 10, 2013, Pages 4663-4668

  Liu, Yi Chang ^a,b   Hsiao, Hui Hua ^a,b   Chang, Chao Sung ^a,b   Liu, Ta Chih ^a,b   Yang, Wen Chi ^a,b   Hsu, Jui Feng ^a   Huang, Chiung Tang ^a   Cho, Shih Feng ^a   Wu, Cheng Han ^a   Tsai, Yu Fen ^a   Lin, Sheng Fung ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Allotransplantation; Chronic myeloid leukemia; Hematopoietic stem cell transplantation; Imatinib; Tyrosine kinase inhibitor

Indexed keywords

BCR ABL PROTEIN; IMATINIB; IMMUNOSUPPRESSIVE AGENT; INTERFERON;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLONAL EVOLUTION; CONTROLLED STUDY; DRUG RESPONSE; DRUG TREATMENT FAILURE; GENE MUTATION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION COMPLICATION; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRISOMY 8;

ALLOTRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMATINIB; TYROSINE KINASE INHIBITOR;

ALLOGRAFTS; ANTINEOPLASTIC AGENTS; BENZAMIDES; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MULTIVARIATE ANALYSIS; PIPERAZINES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PYRIMIDINES; RETROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 84891354952     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417, 2006.
2. Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J, Kolb HJ, Lahaye T, Maywald O, Reiter A, Hossfeld DK, Huber C, Löffler H, Pralle H, Queisser W, Tobler A, Nerl C, Solenthaler M, Goebeler ME, Griesshammer M, Fischer T, Kremers S, Eimermacher H, Pfreundschuh M, Hirschmann WD, Lechner K, Wassmann B, Falge C, Kirchner HH and Gratwohl A: Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia. Blood 109: 4686-4692, 2007.
3. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R: Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27: 6041-6051, 2009.
4. Venepalli N, Rezvani K, Mielke S and Savani BN: Role of allo-SCT for CML in 2010. Bone Marrow Transplant 45: 1579-1586, 2010.
5. Pavlu J, Szydlo RM, Goldman JM and Apperley JF: Three decades of transplantation for chronic myeloid leukemia: What have we learned? Blood 117: 755-763, 2011.
6. Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R, Kolb HJ, Ho AD, Falge C, Holler E, Schlimok G, Zander AR, Arnold R, Kanz L, Dengler R, Haferlach C, Schlegelberger B, Pfirrmann M, Müller MC, Schnittger S, Leitner A, Pletsch N, Hochhaus A, Hasford J and Hehlmann R: Allogeneic hematopoietic stem cell transplantation (allo-SCT) for chronic myeloid leukemia in the imatinib era: Evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 115: 1880-1885, 2010.
7. Jabbour E, Cortes J, Santos FP, Jones D, O'Brien S, Rondon G, Popat U, Giralt S, Kebriaei P, Jones RB, Kantarjian H, Champlin R and de Lima M: Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 117: 3641-3647, 2011.
8. Tam CS, Kantarjian H, Garcia-Manero G, Borthakur G, O'Brien S, Ravandi F, Shan J and Cortes J: Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 112: 516-518, 2008.
9. Jabbour E, Kantarjian H, O'Brien S, Shan J, Garcia-Manero G, Wierda W, Ravandi F, Borthakur G, Rios MB and Cortes J: Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood 117: 1822-1827, 2011.
10. Milojkovic D, Nicholson E, Apperley JF, Holyoake TL, Shepherd P, Drummond MW, Szydlo R, Bua M, Foroni L, Reid A, Khorashad JS, de Lavallade H, Rezvani K, Paliompeis C, Goldman JM and Marin D: Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 95: 224-231, 2010.